Literature DB >> 34282314

Proteomics-based target identification of natural products affecting cancer metabolism.

Makoto Muroi1, Hiroyuki Osada2.   

Abstract

The Warburg effect, a widely known characteristic of cancer cells, refers to the utilization of glycolysis under aerobic conditions for extended periods of time. Recent studies have revealed that cancer cells are capable of reprogramming their metabolic pathways to meet vigorous metabolic demands. New anticancer drugs that target the complicated metabolic systems of cancer cells are being developed. Identifying the potential targets of novel compounds that affect cancer metabolism may enable the discovery of new therapeutic targets for cancer treatment, and hasten the development of anticancer drugs. Historically, various drug screening techniques such as the analysis of a compound's antiproliferative effect on cancer cells and proteomic methods, that enable target identification have been used to obtain many useful drugs from natural products. Here, we review proteomics-based target identification methods applicable to natural products that affect cancer metabolism.
© 2021. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34282314     DOI: 10.1038/s41429-021-00437-y

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  55 in total

Review 1.  Mitochondrial Metabolism as a Target for Cancer Therapy.

Authors:  Karthik Vasan; Marie Werner; Navdeep S Chandel
Journal:  Cell Metab       Date:  2020-07-14       Impact factor: 27.287

2.  L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.

Authors:  Eun-Hee Shim; Carolina B Livi; Dinesh Rakheja; Jubilee Tan; Daniel Benson; Vishwas Parekh; Eun-Young Kho; Arindam P Ghosh; Richard Kirkman; Sadanan Velu; Shilpa Dutta; Balachandra Chenna; Shane L Rea; Robert J Mishur; Qiuhua Li; Teresa L Johnson-Pais; Lining Guo; Sejong Bae; Shi Wei; Karen Block; Sunil Sudarshan
Journal:  Cancer Discov       Date:  2014-09-02       Impact factor: 39.397

Review 3.  From Krebs to clinic: glutamine metabolism to cancer therapy.

Authors:  Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2016-07-29       Impact factor: 60.716

Review 4.  Otto Warburg's contributions to current concepts of cancer metabolism.

Authors:  Willem H Koppenol; Patricia L Bounds; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2011-04-14       Impact factor: 60.716

5.  Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.

Authors:  Matt I Gross; Susan D Demo; Jennifer B Dennison; Lijing Chen; Tania Chernov-Rogan; Bindu Goyal; Julie R Janes; Guy J Laidig; Evan R Lewis; Jim Li; Andrew L Mackinnon; Francesco Parlati; Mirna L M Rodriguez; Peter J Shwonek; Eric B Sjogren; Timothy F Stanton; Taotao Wang; Jinfu Yang; Frances Zhao; Mark K Bennett
Journal:  Mol Cancer Ther       Date:  2014-02-12       Impact factor: 6.261

6.  Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.

Authors:  J E Mortimer; F Dehdashti; B A Siegel; J A Katzenellenbogen; P Fracasso; M J Welch
Journal:  Clin Cancer Res       Date:  1996-06       Impact factor: 12.531

7.  An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

Authors:  Jennifer R Molina; Yuting Sun; Marina Protopopova; Sonal Gera; Madhavi Bandi; Christopher Bristow; Timothy McAfoos; Pietro Morlacchi; Jeffrey Ackroyd; Ahmed-Noor A Agip; Gheath Al-Atrash; John Asara; Jennifer Bardenhagen; Caroline C Carrillo; Christopher Carroll; Edward Chang; Stefan Ciurea; Jason B Cross; Barbara Czako; Angela Deem; Naval Daver; John Frederick de Groot; Jian-Wen Dong; Ningping Feng; Guang Gao; Jason Gay; Mary Geck Do; Jennifer Greer; Virginia Giuliani; Jing Han; Lina Han; Verlene K Henry; Judy Hirst; Sha Huang; Yongying Jiang; Zhijun Kang; Tin Khor; Sergej Konoplev; Yu-Hsi Lin; Gang Liu; Alessia Lodi; Timothy Lofton; Helen Ma; Mikhila Mahendra; Polina Matre; Robert Mullinax; Michael Peoples; Alessia Petrocchi; Jaime Rodriguez-Canale; Riccardo Serreli; Thomas Shi; Melinda Smith; Yoko Tabe; Jay Theroff; Stefano Tiziani; Quanyun Xu; Qi Zhang; Florian Muller; Ronald A DePinho; Carlo Toniatti; Giulio F Draetta; Timothy P Heffernan; Marina Konopleva; Philip Jones; M Emilia Di Francesco; Joseph R Marszalek
Journal:  Nat Med       Date:  2018-06-11       Impact factor: 53.440

8.  Metformin induces degradation of mTOR protein in breast cancer cells.

Authors:  Mohamed Alalem; Alpana Ray; Bimal K Ray
Journal:  Cancer Med       Date:  2016-10-17       Impact factor: 4.452

9.  Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate.

Authors:  Tom H Peeters; Krissie Lenting; Vincent Breukels; Sanne A M van Lith; Corina N A M van den Heuvel; Remco Molenaar; Arno van Rooij; Ron Wevers; Paul N Span; Arend Heerschap; William P J Leenders
Journal:  Cancer Metab       Date:  2019-05-20

Review 10.  Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.

Authors:  Danielle Golub; Nishanth Iyengar; Siddhant Dogra; Taylor Wong; Devin Bready; Karen Tang; Aram S Modrek; Dimitris G Placantonakis
Journal:  Front Oncol       Date:  2019-05-17       Impact factor: 6.244

View more
  1 in total

1.  Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.

Authors:  Yuting Kuang; Na Ye; Armita Kyani; Mats Ljungman; Michelle Paulsen; Haijun Chen; Mingxiang Zhou; Christopher Wild; Haiying Chen; Jia Zhou; Nouri Neamati
Journal:  J Med Chem       Date:  2022-04-19       Impact factor: 8.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.